Key regions: China, Europe, Australia, United States, Germany
The Other Pharmaceuticals market in D-A-CH has seen significant growth in recent years, driven by various factors such as changing customer preferences and local special circumstances.
Customer preferences: Customers in D-A-CH have shown a growing preference for alternative medicines and treatments, leading to an increase in demand for Other Pharmaceuticals. This trend is driven by a desire for natural and holistic remedies, as well as a growing awareness of the potential side effects of traditional pharmaceuticals.
Trends in the market: In Germany, the Other Pharmaceuticals market has seen significant growth due to the country's strong focus on natural and alternative medicine. The market is dominated by small and medium-sized companies that specialize in producing natural remedies and supplements. In Switzerland, the market is driven by a high demand for homeopathic medicines, while in Austria, the market is characterized by a growing interest in herbal remedies.
Local special circumstances: One of the key drivers of the Other Pharmaceuticals market in D-A-CH is the region's strong tradition of natural medicine. This has led to the development of a thriving industry of small and medium-sized companies that specialize in producing natural remedies and supplements. In addition, the region's strict regulations on traditional pharmaceuticals have made it difficult for large pharmaceutical companies to gain a foothold in the market, further contributing to the dominance of smaller players.
Underlying macroeconomic factors: The growth of the Other Pharmaceuticals market in D-A-CH is also influenced by broader macroeconomic factors. For example, the region's aging population has led to a growing demand for natural remedies and supplements, as older consumers seek to maintain their health and wellbeing. In addition, the region's strong economy has allowed consumers to spend more on healthcare, further driving demand for alternative medicines.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
